1. Cellular uptake of liposomes targeted to intercellular adhesion molecule-1 (ICAM-1) on bronchial epithelial cells
- Author
-
Enrico Mastrobattista, L. van Bloois, Daan J.A. Crommelin, Regina Reszka, P.G.M. Bloemen, Gert Storm, and Paul A.J. Henricks
- Subjects
Time Factors ,medicine.drug_class ,Intercellular Adhesion Molecule-1 ,Cell ,Biophysics ,Bronchi ,Biology ,Monoclonal antibody ,Biochemistry ,Cell Line ,Interferon-gamma ,Cell Adhesion ,medicine ,Humans ,Inflammation ,Drug Carriers ,ICAM-1 ,Liposome ,Microscopy, Confocal ,Immunoliposomes ,Cell adhesion molecule ,Antibodies, Monoclonal ,Epithelial Cells ,Cell Biology ,Fluoresceins ,Molecular biology ,In vitro ,Cell biology ,medicine.anatomical_structure ,Liposomes ,Drug delivery ,Adhesion molecules ,Intracellular - Abstract
Previously, it was demonstrated that immunoliposomes, bearing anti-intercellular adhesion molecule-1 (ICAM-1) antibodies (mAb F10.2), can specifically bind to different cell types expressing ICAM-1. In this study, we have quantified the amount of immunoliposomes binding to IFN-gamma activated human bronchial epithelial cells (BEAS-2B) in vitro and studied the subsequent fate of cell-bound anti-ICAM-1 immunoliposomes. We demonstrate that binding of the immunoliposomes to the epithelial cells depends on the liposome concentration used. After binding to the cell surface, the anti-ICAM-1 immunoliposomes are rapidly internalised by the epithelial cells. Sixty percent of cell-bound immunoliposomes were internalised by the epithelial cells within 1 h of incubation at 37 degrees C. The results indicate that ICAM-1 targeted immunoliposomes may be used as carriers for the intracellular delivery of anti-inflammatory drugs to sites of inflammation characterised by an increased expression of ICAM-1.
- Published
- 1999
- Full Text
- View/download PDF